The Endocannabinoid System May Suppress Neuroinflammation and Fight Tumors — A Review of the Mechanisms

This review mapped the endocannabinoid system's relationship with the immune system and cancer biology. The key mechanisms included CB1 and CB2 receptor activation suppressing immune responses through multiple pathways: inhibiting white blood cell proliferation, triggering T cell apoptosis (programmed death), activating macrophages, and reducing pro-inflammatory cytokine secretion.

For neuroinflammatory autoimmune disorders like multiple sclerosis, these immunosuppressive properties pointed toward potential therapeutic use — dampening the overactive immune response that damages myelin. For cancer, the picture was more complex: cannabinoids showed anti-tumor properties in both in vitro (cell culture) and in vivo (animal) studies, including inhibiting tumor cell proliferation, inducing cancer cell death, and reducing tumor blood vessel formation.

The review compiled evidence from clinical trials alongside preclinical work, though it noted that the clinical evidence remained early-stage.

The endocannabinoid system sits at the intersection of neuroscience and immunology. This review showed that cannabinoids don't just affect mood and pain — they fundamentally modulate immune function. For conditions where the immune system attacks the body (autoimmune diseases) or fails to control abnormal growth (cancer), that modulation could theoretically be therapeutic.

But "could theoretically" is doing heavy lifting. The jump from "cannabinoids kill cancer cells in a dish" to "cannabis treats cancer in humans" is enormous, and this review was careful to note that clinical evidence remained limited.